MX2023005081A - Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos. - Google Patents

Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos.

Info

Publication number
MX2023005081A
MX2023005081A MX2023005081A MX2023005081A MX2023005081A MX 2023005081 A MX2023005081 A MX 2023005081A MX 2023005081 A MX2023005081 A MX 2023005081A MX 2023005081 A MX2023005081 A MX 2023005081A MX 2023005081 A MX2023005081 A MX 2023005081A
Authority
MX
Mexico
Prior art keywords
methods
targeting
multispecific antibodies
antibodies
discovering
Prior art date
Application number
MX2023005081A
Other languages
English (en)
Spanish (es)
Inventor
David Campbell
Thomas R Diraimondo
Original Assignee
Janux Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janux Therapeutics Inc filed Critical Janux Therapeutics Inc
Publication of MX2023005081A publication Critical patent/MX2023005081A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023005081A 2020-10-30 2021-10-29 Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos. MX2023005081A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063107942P 2020-10-30 2020-10-30
US202063123327P 2020-12-09 2020-12-09
US202063123329P 2020-12-09 2020-12-09
US202163141268P 2021-01-25 2021-01-25
US202163187719P 2021-05-12 2021-05-12
US202163187699P 2021-05-12 2021-05-12
US202163187690P 2021-05-12 2021-05-12
US202163189843P 2021-05-18 2021-05-18
PCT/US2021/057384 WO2022094299A2 (en) 2020-10-30 2021-10-29 Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023005081A true MX2023005081A (es) 2023-06-15

Family

ID=81384468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005081A MX2023005081A (es) 2020-10-30 2021-10-29 Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos.

Country Status (8)

Country Link
US (1) US20230406937A1 (enExample)
EP (1) EP4237013A4 (enExample)
JP (1) JP2023548443A (enExample)
KR (1) KR20230136913A (enExample)
AU (1) AU2021369835A1 (enExample)
CA (1) CA3196726A1 (enExample)
MX (1) MX2023005081A (enExample)
WO (1) WO2022094299A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
MX2023013382A (es) 2020-04-04 2024-01-30 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras.
US20240043536A1 (en) * 2020-12-08 2024-02-08 Janux Therapeutics, Inc. Peptide compositions and methods for anti-cd3 binding domains
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
US20240228620A1 (en) 2022-10-06 2024-07-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
EP4615514A2 (en) * 2022-11-10 2025-09-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
WO2024100451A2 (en) * 2022-11-11 2024-05-16 Janux Therapeutics, Inc. Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
CN121532427A (zh) * 2023-05-18 2026-02-13 首尔大学校产学协力团 抗cd40l/抗cd28双特异性抗体及其用途
WO2025026356A1 (zh) * 2023-07-31 2025-02-06 百奥泰生物制药股份有限公司 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用
WO2025090973A2 (en) * 2023-10-27 2025-05-01 Xencor, Inc. Anti-trop2 x anti-pdl1 x anti-cd28 antibodies
TW202528349A (zh) * 2023-11-03 2025-07-16 美商詹努克斯治療有限公司 用於靶向psma及cd28之抗體及其用途
AR134209A1 (es) * 2023-11-03 2025-12-10 Janux Therapeutics Inc Anticuerpos dirigidos cd28 y usos de los mismos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114181309B (zh) * 2015-05-21 2024-07-30 鳄鱼生物科学公司 新型多肽
JP2018516969A (ja) * 2015-06-12 2018-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
WO2018014001A1 (en) * 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
EP3645050A4 (en) * 2017-06-25 2021-08-11 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
AU2018296067B2 (en) * 2017-07-06 2021-06-10 Merus B.V. Binding molecules that modulate a biological activity expressed by a cell
CN112513077B (zh) * 2018-07-09 2025-05-16 上海岸迈生物科技有限公司 高效表达的egfr和pd-l1双特异性结合蛋白
UA128001C2 (uk) * 2018-12-21 2024-03-06 Ф. Хоффманн-Ля Рош Аг Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
WO2020127628A1 (en) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted superagonistic cd28 antigen binding molecules
CA3134335A1 (en) * 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies

Also Published As

Publication number Publication date
EP4237013A2 (en) 2023-09-06
EP4237013A4 (en) 2025-02-26
US20230406937A1 (en) 2023-12-21
JP2023548443A (ja) 2023-11-16
WO2022094299A2 (en) 2022-05-05
WO2022094299A3 (en) 2022-09-29
AU2021369835A9 (en) 2024-07-11
KR20230136913A (ko) 2023-09-27
AU2021369835A1 (en) 2023-06-01
CA3196726A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
MX2023005081A (es) Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos.
PH12022551298A1 (en) Antibodies specific for cd47, pd-l1, and uses thereof
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
WO2018234793A3 (en) Antibodies
MY198034A (en) Tumor-targeted agonistic cd28 antigen binding molecules
WO2020010250A3 (en) Anti-tcr antibody molecules and uses thereof
EP4527854A3 (en) Antibodies against pd-l1
NZ754051A (en) Novel antibodies and uses thereof
CL2019001517A1 (es) Anticuerpos y métodos de su utilización.
MX2019002946A (es) Anticuerpos anti-pd-1 y sus usos.
WO2018237148A8 (en) Multispecific antibodies that target hiv gp120 and cd3
WO2021022304A3 (en) Bispecific anti lrrc15 and cd3epsilon antibodies
ZA201804654B (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
EP4218802A3 (en) Conjugates for targeted cell surface editing
JOP20200157A1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
MY192392A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
MX2022007613A (es) Union de anticuerpos de cadena pesada a cd38.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
WO2022084331A3 (en) Novel ligands for asialoglycoprotein receptor
MX2021005085A (es) Formulacion de anticuerpo.